Votre recherche pour: HyClone products (Cytiva)

Regulatory Agencies and Approvals ASCII: American Standard Code for Information Interchange method of encoding characters into 7 or 8 binary bits (typically 7 bits plus an 8th bit for parity). ANSI: The American National Standards Institute is a p...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Continued research Moving your research forward relies on the right products and planning precisely when and where needed. Avantor is your complete resource for everything you need to ensure optimized research workflows – from consumables instrume...

Final fill for vaccines Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepared in an ISO...

Final fill for recombinant proteins Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepar...

Final fill for vaccines Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepared in an ISO...

Final fill for mAbs Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepared in an ISO Cla...

Final fill for recombinant proteins Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepar...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Assays for final fill Control is influenced by aseptic procedures followed in the production environment and is adhered to by employee training gowning cleaning and environmental control. Process validation steps are followed to ensure an acceptab...

Solutions to manage complexity in global single-use supply chain for vaccines manufacturing Webinar On demand Replay Single-use systems have been proven to enable a more flexible cost-effective approach to manufacturing monoclonal antibodies (mAbs...

Final fill for gene therapy To meet these requirements products must be prepared in an ISO Class 5 environment and meet USP71 USP85 and USP758 requirements to be sterile pyrogen-free and particulate-free. They must also be validated for use in sto...

Continued research Moving your research forward relies on the right products and planning precisely when and where needed. Avantor is your complete resource for everything you need to ensure optimized research workflows – from consumables instrume...

Upstream processing for microbial-based recombinant proteins Using microbial fermentation for the development and manufacture of recombinant proteins keeps on showing advantages e.g for the expression of proteins that do not require post-translati...

Success story Avantor accelerates Cell and Gene Therapy (C>) production Avantor Services Lab and production services CHALLENGE A global pharmaceutical company set an ambitious strategic goal of transitioning from Cell and Gene Therapy (C>) con...